Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CSL ( (AU:CSL) ) has issued an announcement.
CSL Limited has announced an update regarding its ongoing on-market buy-back program. As of November 12, 2025, the company has repurchased a total of 1,846,467 of its ordinary fully paid securities, with an additional 50,512 bought back on the previous day. This buy-back initiative is part of CSL’s strategic efforts to manage its capital structure and enhance shareholder value.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$225.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, focusing on the development and manufacturing of innovative medicines and vaccines. The company is known for its work in plasma therapies, vaccines, and pharmaceuticals, serving a global market with a strong emphasis on research and development.
Average Trading Volume: 1,363,726
Technical Sentiment Signal: Sell
Current Market Cap: A$86.86B
See more data about CSL stock on TipRanks’ Stock Analysis page.